It is well established that most people recover soon after a mild traumatic brain injury (mTBI), yet protracted neuropsychological impairment is evident in many individuals. We sought to elucidate the relationship between apathy and neuropsychological impairment and disability as it pertains to real-world function in patients who sustained a mTBI reporting and demonstrating protracted neuropsychological impaired (i.e., more than three months post-injury). We employed a battery of neuropsychological and psychological measures, along with a measure of apathy in 104 patients who sustained a mTBI reporting neuropsychological complaints (38 in the not disabled group and 66 in the disabled group). Their ability to return to work was used as proxy for real-world disability. Specific deficits in verbal fluency, memory, and information processing predicted real-world disability but apathy did not, suggesting that psychological factors may play less of a mediating role than specific neuropsychological factors in the relationship between impairment and real world disability. Our research furthers our understanding of the cognitive and psychological differences that exist in patients with mTBI who have real-world disability compared to those who do not.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/23279095.2016.1225216 | DOI Listing |
J Cachexia Sarcopenia Muscle
February 2025
Center for Health Information Partnerships, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Background: Cancer-associated cachexia can inhibit immune checkpoint inhibitor (ICI) therapy efficacy. Cachexia's effect on ICI therapy has not been studied in large cohorts of cancer patients aside from lung cancer. We studied associations between real-world routinely collected clinical cachexia markers and disability-free, hospitalization-free and overall survival of cancer patients.
View Article and Find Full Text PDFBMC Geriatr
January 2025
Department of Pharmacy, Faculty of Pharmacy, Musashino University, 1-1-20 Shinmachi Nishitokyo-Shi, Tokyo, 202-8585, Japan.
Background: Edaravone is marketed in nine countries, although only Japan has approved edaravone for improvement of neurological symptom, disability of activities of daily living (ADL), and functional disability associated with acute stroke. This study aimed to elucidate the association of edaravone use with ADL using real-world data of older patients with atherothrombotic stroke.
Methods: This retrospective observational research using the Medical Data Vision database in Japan included patients aged 65 years and older who had acute ischemic stroke of the atherothrombotic subtype.
Arq Neuropsiquiatr
January 2025
Universidade Federal do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Centro de Estudos em Paramiloidose Antônio Rodrigues de Mello, Rio de Janeiro RJ, Brazil.
Background: Tafamidis is a kinetic stabilizer that binds to the transthyretin (TTR) gene, inhibiting its dissociation. It is the only disease-modifying treatment for hereditary TTR amyloidosis with peripheral neuropathy (ATTRv-PN) available in the National Therapeutic Form (Formulário Terapêutico Nacional, FTN, in Portuguese) of the Brazilian Unified Health System (Sistema Único de Saúde, SUS, in Portuguese).
Objective: To assess if the efficacy and safety of tafamidis in the Brazilian real-world experience are comparable to the results of clinical trials.
Neurol Clin Pract
April 2025
Brigham MS Center (MKH), Harvard Medical School, Boston, MA; Georgia State University (MCM), Atlanta; Brigham and Women's Hospital (TDM, JP-P, CS, JZ), Boston, MA; Massachusetts General Hospital (ECK), Harvard Medical School, Boston, MA; University of Vermont (AJS), Burlington; Elliot Lewis MS Center (EL, JK), Wellesley, MA; University of Massachusetts (CI, IB), Worcester, MA; Novartis Pharmaceuticals (JMS), Jersey City, NJ; Concord Hospital (AC), NH; and University of British Columbia (ADS), Vancouver, BC, Canada.
Background And Objectives: Multiple sclerosis (MS) affects more than 1 million people in the United States, including reproductive-age women. There has been a paucity of prospective, pregnancy registries based on MS disease rather than medication exposures. A prospective MS pregnancy registry (PREG-MS) was established in 2017 as a prospective, single-cohort, real-world MS pregnancy registry in New England States of the United States, with goals to evaluate (1) course of MS and disease-modifying therapies (DMT) use during conception attempts and in the peripartum period, (2) pregnancy outcomes in women with MS (WwMS), and (3) longer-term developmental outcomes in offspring of WwMS.
View Article and Find Full Text PDFBMJ Open
January 2025
Pharmaceutical Sciences Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran (the Islamic Republic of).
Objectives: The main objective was to evaluate the cost-effectiveness of various medical therapy combinations in managing chronic coronary syndrome (CCS) in Iran, based on real-world and patient-level data.
Design: A cost-utility analysis employing a Markov model was conducted using data from a retrospective cohort study.
Setting: The study was conducted in the healthcare setting of Iran, focusing on primary and secondary care.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!